echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Adjuvant Keytruda gets FDA approval to treat more melanoma patients

    Adjuvant Keytruda gets FDA approval to treat more melanoma patients

    • Last Update: 2022-02-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On December 4, the U.


    This approval is based on positive results from a randomized, double-blind, placebo-controlled Phase 3 clinical trial


    Image source: Merck's official website

    Patients with stage IIB or IIC melanoma carry deep or ulcerated tumors in situ


    The use of Keytruda in the treatment of patients with earlier stage cancer is one of the important directions of research and development of Merck & Co.


    Note: The original text has been deleted

    References:

    [1] FDA Approves Adjuvant Pembrolizumab for Stage IIB or IIC Melanoma.


    [2] Keytruda Label.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.